FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to obtaining of albumin variants, which can be used in medicine. Polypeptides having at least 90% identity with the original human albumin are obtained, as well as their conjugates, fused proteins, associates, nanoparticles and pharmaceutical compositions.
EFFECT: invention allows to obtain variants of albumin with stronger binding affinity for FcRn and longer half-life in plasma as compared to the original albumin.
51 cl, 24 dwg, 20 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
ALBUMIN VARIANTS | 2013 |
|
RU2670063C2 |
VERSIONS OF ALBUMIN | 2010 |
|
RU2607374C2 |
FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
CD40L-SPECIFIC FRAMEWORK STRUCTURES DERIVED FROM Tn3, AND METHODS OF USE THEREOF | 2012 |
|
RU2826189C2 |
CD40L-SPECIFIC CARCASS STRUCTURES DERIVED FROM Tn3, AND METHODS FOR USE THEREOF | 2012 |
|
RU2704992C2 |
IMPROVED SUBSTANCES BINDING TO SERUM ALBUMIN | 2018 |
|
RU2789495C2 |
FUSION SERPINE POLYPEPTIDES AND METHODS FOR THEIR APPLICATION | 2012 |
|
RU2642310C2 |
FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
POLYPEPTIDES | 2011 |
|
RU2577964C2 |
Authors
Dates
2018-04-17—Published
2012-05-04—Filed